Literature DB >> 29058824

Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C-Terminal Inhibitors.

Katherine M Byrd1, Caitlin N Kent1, Brian S J Blagg1.   

Abstract

The design, synthesis, and biological evaluation of stilbene-based novobiocin analogues is reported. Replacement of the biaryl amide side chain with a triazole side chain produced compounds that exhibited good antiproliferative activities. Heat shock protein 90 (Hsp90) inhibition was observed when N-methylpiperidine was replaced with acyclic tertiary amines on the stilbene analogues that also contain a triazole-derived side chain. These studies revealed that ≈24 Å is the optimal length for compounds that exhibit good antiproliferative activity as a result of Hsp90 inhibition.
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  C-terminal inhibitors; anticancer agents; heat shock protein 90; stilbene

Mesh:

Substances:

Year:  2017        PMID: 29058824      PMCID: PMC5892432          DOI: 10.1002/cmdc.201700630

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  55 in total

1.  Alternative approaches to Hsp90 modulation for the treatment of cancer.

Authors:  Jessica A Hall; Leah K Forsberg; Brian S J Blagg
Journal:  Future Med Chem       Date:  2014-09       Impact factor: 3.808

Review 2.  Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery.

Authors:  William B Pratt; David O Toft
Journal:  Exp Biol Med (Maywood)       Date:  2003-02

Review 3.  Hsp90 isoforms: functions, expression and clinical importance.

Authors:  Amere Subbarao Sreedhar; Eva Kalmár; Péter Csermely; Yu-Fei Shen
Journal:  FEBS Lett       Date:  2004-03-26       Impact factor: 4.124

Review 4.  Heat-shock protein 90, a chaperone for folding and regulation.

Authors:  D Picard
Journal:  Cell Mol Life Sci       Date:  2002-10       Impact factor: 9.261

Review 5.  Targeting the dynamic HSP90 complex in cancer.

Authors:  Jane Trepel; Mehdi Mollapour; Giuseppe Giaccone; Len Neckers
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

6.  Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.

Authors:  Huiping Zhao; Gaurav Garg; Jinbo Zhao; Elisabetta Moroni; Antwan Girgis; Lucas S Franco; Swapnil Singh; Giorgio Colombo; Brian S J Blagg
Journal:  Eur J Med Chem       Date:  2014-10-14       Impact factor: 6.514

Review 7.  Organelle-specific Hsp90 inhibitors.

Authors:  Young Ho Seo
Journal:  Arch Pharm Res       Date:  2015-07-22       Impact factor: 4.946

8.  Modulation of Hsf1 activity by novobiocin and geldanamycin.

Authors:  Renaud Conde; Zachery R Belak; Manoj Nair; Ruth F O'Carroll; Nick Ovsenek
Journal:  Biochem Cell Biol       Date:  2009-12       Impact factor: 3.626

9.  Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold.

Authors:  Sanket J Mishra; Suman Ghosh; Andrew R Stothert; Chad A Dickey; Brian S J Blagg
Journal:  ACS Chem Biol       Date:  2016-12-13       Impact factor: 5.100

10.  KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells.

Authors:  Shary N Shelton; Mary E Shawgo; Shawna B Matthews; Yuanming Lu; Alison C Donnelly; Kristen Szabla; Mehmet Tanol; George A Vielhauer; Roger A Rajewski; Robert L Matts; Brian S J Blagg; John D Robertson
Journal:  Mol Pharmacol       Date:  2009-09-09       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.